The webinar will be covered in two parts:
Droplet digital PCR (ddPCR) for BCR‑ABL1 and its use in detecting minimal residual disease (MRD)
During this webinar we will discuss the pros and cons of using Droplet Digital PCR for detection and monitoring of BCR‑ABL1 in CML, including clinical implications and patient outcome.
Silvio Veronese, PhD,
Head, Molecular Pathology Unit, Division of Anatomical and Surgical Pathology Niguarda Hospital, Milan, Italy
Silvio Veronese's main fields of interest concern i) the molecular characterization of haematological diseases and solid tumors and ii) the search for novel biomarkers of clinical utility for targeted therapies. His lab is a reference lab for molecular diagnostics in Italy. He authored/co‑authored several articles in high impact journals.
Digital PCR for the Measurement of BCR‑ABL1 in CML: A New Dawn?
We will review data generated from a large scale, international, interlaboratory study that aimed to establish whether Reverse Transcriptase‑droplet digital PCR using the QXDx BCR‑ABL %IS kit is a viable alternative to RT‑qPCR for CML MRD monitoring.
Stuart Scott, BSc
Centre Manager, UKNEQAS for Leucocyte Immunophenotyping, Sheffield, United Kingdom
Stuart Scott has had a long career in the genetics field, with the last 8 years being at a prestigious External Quality Assessment (EQA) provider. He manages the delivery of EQA services to both molecular haemato‑oncology laboratories and flow cytometric laboratories for Leucocyte Immunophenotyping.